Old drug, new trick? metformin may help seniors regain muscle
NCT ID NCT06185179
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests whether metformin, a widely used diabetes medication, can improve muscle regrowth in older adults after a period of inactivity (like bed rest). Fifty volunteers aged 60 and older will receive either metformin or a placebo during recovery. The goal is to see if metformin helps the thigh muscle recover more fully, potentially reducing fall risk and loss of independence.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Metformin (a common diabetes drug)
- What this could lead to
- If it works, this could point toward a simple, affordable way to help older adults regain muscle strength after periods of inactivity.
- What could go wrong
- This is a very early, small trial (50 people) testing a short-term effect. Metformin is generally safe but may cause stomach upset; it's not proven yet for muscle recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
May 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age between 60y and older 2. BMI: \<30 kg/m2 3. Good general medical health, ambulatory and in independent living setting 4. Adequate upper body strength to use assistive walking device (crutches, walker, etc) as assessed by PI/staff during screening 5. Clinical Frailty Scale score \< 3 6. Mini-Cog score \> 3 Exclusion Criteria: 1. History of cardiovascular disease (e.g., CHF, CAD, MI, CVA) 2. History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes (Treated hypo/hyperthyroid for at least 6 months will be permitted) 3. History of kidney disease or failure (CKD \> stage 4; serum creatinine \>1.5mg/dL) 4. History of vascular disease 5. Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III 6. Use of anticoagulant therapy (e.g., Coumadin, heparin) 7. Uncontrolled hypertension - Elevated systolic pressure \>150 or a diastolic blood pressure \> 100 8. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators) 9. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma 10. Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids will be permitted) 11. Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement will be permitted) 12. Inability to abstain from smoking or vaping for duration of study 13. Currently taking estrogen products (topical estrogen products will be permitted) 14. Currently on weight loss diet or medication 15. History of stroke with motor disability 16. A recent history (\<12 months) of GI bleed 17. History of liver disease or AST/ALT 2 times above the normal limit 18. History of respiratory disease (acute upper respiratory infection, history of chronic lung disease) 19. Any staff members who report directly to the principal investigators
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Muscle atrophy or weakness are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe a muscle protein that may hold clues to Age-Related weakness
- Bedrest be gone? gamified therapy aims to keep seniors moving in the hospital
- Can ancient herbs outshine modern supplements for frail seniors?
- Could donor cells boost rotator cuff repair? early trial begins
- Shock therapy for knees? device aims to rebuild muscle after ACL repair